

# **Financial Tear Sheet**

### **Corporate Profile**

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company's lead FDA approved commercial product, NUZYRA™ (omadacycline) is a once-daily intravenous and oral antibiotic for the treatment of adult patients with CABP and ABSSSI caused by susceptible pathogens. Paratek is also studying NUZYRA™ for the treatment of urinary tract infections (UTI).

Paratek has submitted a marketing authorization application for omadacycline in the European Union. Paratek has entered into a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax.

Paratek's second FDA approved commercial product, SEYSARA™ (sarecycline), is marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. Paratek retains development and commercialization rights to sarecycline in the rest of the world.

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

#### Stock Information

#### PRTK (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$6.25** 

Change (%) ▼ 0.15 (2.34%)

Volume 470,088


52 Week Low \$4.50

Market Cap \$202,599,856

Rolling EPS -3.57

PE Ratio N/A

Shares Outstanding 32,415,977



#### **Recent Paratek Pharmaceuticals News & Events**

03/18/19 - 8:01 a.m.
Paratek Pharmaceuticals Announces
Management Change

03/01/19 - 4:30 p.m.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

03/01/19 - 8:00 a.m.

Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference There are currently no events scheduled.

## **SEC Filings**

Filing Date	Form
03/18/19	CT ORDER
03/18/19	8-K
03/06/19	S-8
03/06/19	10-K

## Management

Michael F. Bigham Chief Executive Officer

and Chairman of the

Board

Evan Loh, M.D. President, Chief

Operating Officer and Chief Medical Officer

Douglas W. Pagán Chief Financial Officer

Adam Woodrow Chief Commercial

Officer

William Haskel General Counsel and

**Corporate Secretary** 

Randy Brenner Senior Vice President

- Regulatory, Quality

and Technical Operations

Evan Tzanis Chief Development

Officer

Jason Burdette Vice President -

**Technical Operations** 

Jeanne Jew Senior Vice President

- Business Development

Raj Padmanabhan Vice President -

Information Technology

Susan Perkins, J.D. Vice President -

Intellectual Property

Christine Vice President -

R. Coyne, MBA Marketing

Sarah Higgins Vice President -

Controller

Paul McGovern, M.D. Vice President -

Clinical and Medical

**Affairs** 

Steve Sandor, MBA, Vice President -

J.D. Market Access and

Trade

Judith Vice President,

N. Steenbergen, PhD Medical Strategy and

Communications

Data provided by Nasdaq. Minimum 15 minutes delayed.